drug_type
RELEVANT_DRUG
intervention_type
Antibody–drug conjugate (biologic)
drug_description
A B7-H3–targeted antibody–drug conjugate consisting of a human IgG1 monoclonal antibody to B7-H3 (CD276) linked to a deruxtecan payload (exatecan-derived topoisomerase I inhibitor); binding to B7-H3 leads to internalization and release of the payload, causing topo-I–mediated DNA damage and apoptosis with potential bystander effect.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
B7-H3–targeted IgG1 antibody–drug conjugate; the antibody binds B7-H3 (CD276) on tumor cells, is internalized, and a cleavable linker releases a deruxtecan (exatecan-derived) topoisomerase I inhibitor payload that causes DNA damage and apoptosis, with potential bystander cytotoxicity.
drug_name
Ifinatamab deruxtecan (I-DXd)
nct_id_drug_ref
NCT06203210